Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1992-03-16
1996-07-30
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 54, 514 59, 536 21, 536 53, 536 54, 536 55, 536 551, 536 553, A61K 31725
Patent
active
055411665
ABSTRACT:
A method of anti-metastatic and/or anti-inflammatory treatment of an animal or human patient comprises administration to the patient of an effective amount of at least one sulphated polysaccharide which blocks or inhibits endoglycosidase, particularly heparanase, activity. Suitable sulphated polysaccharides include heparin and modified heparin, fucoidan, pentosan sulphate, dextran sulphate and carrageenan lambda.
REFERENCES:
patent: 4710493 (1987-12-01), Landsberger
patent: 4757056 (1988-07-01), Van Gorp et al.
patent: 4760066 (1988-07-01), Busse et al.
patent: 4820693 (1989-04-01), Gillespie
patent: 4882318 (1989-11-01), Vlodavsky et al.
The Merck Index, 9th, 1976, see Monographs 1861, 2212, 2907, 4510 and 4634 at pp. 238, 286, 387, 607, 608, 624.
Patents Abstracts of Japan, C 324, p. 165, JP,A, 60-174729.
Suemasu et al., "Inhibitive Effect of Heparin and Dextran Sulfate on Experimental Pulmonary Metastases,"Chemical Abstracts, vol. 73, No. 3 (Jul.20, 1970), p. 209, Abstract 12953h.
Irimura et al., "Chemically Modified Heparins as Inhibitors of Heparan Sulfate Specific Endo-.beta.-glucuronidas (Heparanase) of Metastatic Melanoma Cells", Biochemistry, vol. 25 (1986), pp. 5322-5328.
Bar-Ner et al., "Inhibition of Heparitinase Mediated Degradation of Extracellular Matrix Heparan Sulfate by Non Anticoagulant Heparin Species", Thrombosis Research, Suppl. VI (1986), p. 117, Abstract No. 231.
Yamamoto et al. Japan. J. Exp. Med. 1984, 54 (4), pp. 143-151.
Giroud et al; Therapie 28:889-905 (1973).
Fransson et al: Eur. J. Blochem. 106:59-69 (1980).
Sy et al; Cell. Immunoz. 82:23-32 (1983).
Matzner et al; Thromb. Haemostas, 52(2):134-137 (1984).
Casu et al. Arzneim. Forsch/Drug Res. 36 (I), No. 4: 637-642 (1986).
Castellot, Jr. et al; J. Cell. Biol. 102:1979-1984 (1986).
Matzner et al; Chemical Abstracts 103:3206 of (1985).
Brestel et al; Journal of Immunology 131(5):2515-2519 (1983).
Folkman et al; Science 221: 719-725 (1983).
Sy et al; Cellular Immunology 82:23-32 (1983).
Irimura et al; Biochemistry 25(18):5322-5328 (1986).
Goldberg et al; Anuals of The New York Academy of Science 463(Colloq. Biol. Sci.):289-91 (1986).
Gorelik; Cancer Research 47:809-815 (1 Feb. 1987).
Millar et al; J. Med. 5:23-31 (1974).
Tsubura et al; Gann 67:849-856 (1976).
Tsubura et al; Cancer Inasion and Metastasls: Biologic Mechanisms and Therapy, pp. 367-381 (1977).
Suemasu; Gann (Monograph on Cancer Research) 20:163-172 (1977).
Todorutiu et al; Rev. Roum. Morphol. Empryol. Physiol. 24(2):157-160 (1978).
Kobayash et al; Tokushima J. Exp. Med. 26:41-51 (1979).
Yamashita et al; Dev. Oncol. 4(Metastasis) :127-131 (1980).
Drago et al; J. Surg. Onc. 24:33-35 (1983).
Drago et al; Anticancer Research 4:171-172 (1984).
Gorelik et al; Int. J. Cancer 33:87-94 (1984).
Milas et al; Clin. Expl. Metastasis 3(4):247-255 (1985).
Sylvester et al; Proc. West. Pharmacol. Soc. 29:121-123 (1986).
Parish et al; Int. J. Cancer 40:511-518 (1987).
Savion et al; J. Cell. Ansiol. 130:77-84 (1987).
Coombe et al; Int. J. Cancer 39(1):82-88 (1987).
Parish Christopher R.
Snowden John M.
Fonda Kathleen Kahler
Robinson Douglas W.
The Australian National University
LandOfFree
Sulphated polysaccharides having anti-metastatic and/or anti-inf does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulphated polysaccharides having anti-metastatic and/or anti-inf, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulphated polysaccharides having anti-metastatic and/or anti-inf will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1658626